Replication-competent vectors and empty virus-like particles

New retroviral vector designs for cancer gene therapy or vaccines

Charlotte Dalba, Bertrand Bellier, Noriyuki Kasahara, David Klatzmann

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Replication-defective vectors based on murine oncoretroviruses were the first gene transfer vectors to be used in successful gene therapies. Despite this achievement, they have two major drawbacks: insufficient efficacy for in vivo gene transfer and insertional mutagenesis. Attempts to overcome these problems have led to two retroviral vector designs of principally opposite character: replication-competent vectors transducing largely intact genomes and genome-free vectors. Replication-competent retroviral vectors have achieved dramatically improved efficacy for in vivo cancer gene therapy and genome-free retroviral vectors expressing different kinds of antigens have proven excellent as immunogens. Current developments aim to improve the safety of the replication-competent vectors and to augment the production efficiency of the genome-free vectors by expression from heterologous viral or non-viral vectors. Together with the continuous advances of classical defective retroviral vectors for ex vivo gene therapy, these developments illustrate that, due to their tremendous design versatility, retroviral vectors remain important vectors for gene therapy applications.

Original languageEnglish (US)
Pages (from-to)457-466
Number of pages10
JournalMolecular Therapy
Volume15
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Cancer Vaccines
Neoplasm Genes
Genetic Therapy
Virion
Genome
Insertional Mutagenesis
Genes
Efficiency
Safety
Antigens

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Replication-competent vectors and empty virus-like particles : New retroviral vector designs for cancer gene therapy or vaccines. / Dalba, Charlotte; Bellier, Bertrand; Kasahara, Noriyuki; Klatzmann, David.

In: Molecular Therapy, Vol. 15, No. 3, 03.2007, p. 457-466.

Research output: Contribution to journalArticle

@article{c78cfe5144bb4f9088483854bd71437c,
title = "Replication-competent vectors and empty virus-like particles: New retroviral vector designs for cancer gene therapy or vaccines",
abstract = "Replication-defective vectors based on murine oncoretroviruses were the first gene transfer vectors to be used in successful gene therapies. Despite this achievement, they have two major drawbacks: insufficient efficacy for in vivo gene transfer and insertional mutagenesis. Attempts to overcome these problems have led to two retroviral vector designs of principally opposite character: replication-competent vectors transducing largely intact genomes and genome-free vectors. Replication-competent retroviral vectors have achieved dramatically improved efficacy for in vivo cancer gene therapy and genome-free retroviral vectors expressing different kinds of antigens have proven excellent as immunogens. Current developments aim to improve the safety of the replication-competent vectors and to augment the production efficiency of the genome-free vectors by expression from heterologous viral or non-viral vectors. Together with the continuous advances of classical defective retroviral vectors for ex vivo gene therapy, these developments illustrate that, due to their tremendous design versatility, retroviral vectors remain important vectors for gene therapy applications.",
author = "Charlotte Dalba and Bertrand Bellier and Noriyuki Kasahara and David Klatzmann",
year = "2007",
month = "3",
doi = "10.1038/sj.mt.6300054",
language = "English (US)",
volume = "15",
pages = "457--466",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Replication-competent vectors and empty virus-like particles

T2 - New retroviral vector designs for cancer gene therapy or vaccines

AU - Dalba, Charlotte

AU - Bellier, Bertrand

AU - Kasahara, Noriyuki

AU - Klatzmann, David

PY - 2007/3

Y1 - 2007/3

N2 - Replication-defective vectors based on murine oncoretroviruses were the first gene transfer vectors to be used in successful gene therapies. Despite this achievement, they have two major drawbacks: insufficient efficacy for in vivo gene transfer and insertional mutagenesis. Attempts to overcome these problems have led to two retroviral vector designs of principally opposite character: replication-competent vectors transducing largely intact genomes and genome-free vectors. Replication-competent retroviral vectors have achieved dramatically improved efficacy for in vivo cancer gene therapy and genome-free retroviral vectors expressing different kinds of antigens have proven excellent as immunogens. Current developments aim to improve the safety of the replication-competent vectors and to augment the production efficiency of the genome-free vectors by expression from heterologous viral or non-viral vectors. Together with the continuous advances of classical defective retroviral vectors for ex vivo gene therapy, these developments illustrate that, due to their tremendous design versatility, retroviral vectors remain important vectors for gene therapy applications.

AB - Replication-defective vectors based on murine oncoretroviruses were the first gene transfer vectors to be used in successful gene therapies. Despite this achievement, they have two major drawbacks: insufficient efficacy for in vivo gene transfer and insertional mutagenesis. Attempts to overcome these problems have led to two retroviral vector designs of principally opposite character: replication-competent vectors transducing largely intact genomes and genome-free vectors. Replication-competent retroviral vectors have achieved dramatically improved efficacy for in vivo cancer gene therapy and genome-free retroviral vectors expressing different kinds of antigens have proven excellent as immunogens. Current developments aim to improve the safety of the replication-competent vectors and to augment the production efficiency of the genome-free vectors by expression from heterologous viral or non-viral vectors. Together with the continuous advances of classical defective retroviral vectors for ex vivo gene therapy, these developments illustrate that, due to their tremendous design versatility, retroviral vectors remain important vectors for gene therapy applications.

UR - http://www.scopus.com/inward/record.url?scp=33847197962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847197962&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300054

DO - 10.1038/sj.mt.6300054

M3 - Article

VL - 15

SP - 457

EP - 466

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -